Cullinan Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGEM research report →
Range $27 – $40
Price Chart
About the company
Cullinan Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
- CEO
- Nadim Ahmed
- IPO
- 2021
- Employees
- 109
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on CGEM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.07B
- P/E
- -5.19
- PEG
- -1.64
- P/S
- 0.00
- P/B
- 3.34
- EV/EBITDA
- -4.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.89%
- ROIC
- -68.50%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-241,648,000
- Net Income
- $-219,879,000-31.4%
- EPS
- $-3.72-19.6%
- OCF Growth
- -21.0%
- FCF Growth
- -21.0%
- 52W High
- $23.19
- 52W Low
- $5.71
- 50D MA
- $19.41
- 200D MA
- $15.38
- Beta
- -0.01
- RSI (14)
- 47
- Avg Volume
- 847.77K
No earnings-call transcripts are available for CGEM yet.
- Free Float
- 71.8%
- Shares Outstanding
- 61.46M
- Float Shares
- 44.16M
of shares held by institutions
193 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bioimpact Capital LLC | 9.73M | ▲ 2.08M |
| Lynx1 Capital Management LP | 8.96M | 0 |
| Bvf Inc/Il | 5.75M | 0 |
| Blackrock, Inc. | 5.23M | ▲ 782.80K |
| Price T Rowe Associates Inc | 3.83M | ▲ 1.80M |
| State Street Corp | 3.67M | ▲ 1.12M |
| Vanguard Group Inc | 3.30M | ▲ 355.18K |
| Kynam Capital Management, LP | 3.11M | 0 |
| Vanguard Capital Management LLC | 2.61M | ▲ 131.03K |
| Rtw Investments, LP | 2.36M | ▲ 658.39K |
| Siren, L.L.C. | 1.89M | ▲ 700.00K |
| Geode Capital Management, LLC | 1.55M | ▲ 179.04K |
Held by 247 ETFs
Biggest fund positions in CGEM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Michaelson Jennifer | other | 4,000 |
| Sep 8, 26 | Michaelson Jennifer | sell | 8,000 |
| Sep 8, 26 | Michaelson Jennifer | other | 4,000 |
| Aug 13, 26 | Michaelson Jennifer | other | 30,000 |
| Aug 13, 26 | Michaelson Jennifer | sell | 30,000 |
| Aug 13, 26 | Michaelson Jennifer | other | 30,000 |
| Jul 6, 26 | Michaelson Jennifer | other | 4,000 |
| Jul 6, 26 | Michaelson Jennifer | sell | 8,000 |
| Jul 6, 26 | Michaelson Jennifer | other | 4,000 |
| Jun 30, 26 | SUMER JACQUELYN L | other | 2,470 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGEM coverage
Recent articles, reports, and earnings notes.
No research on CGEM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGEM report →New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
globenewswire.com · Oct 1
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
seekingalpha.com · Sep 29
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
marketbeat.com · Sep 28
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
globenewswire.com · Sep 24
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com · Sep 21
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM
defenseworld.net · Sep 15
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
seekingalpha.com · Sep 14
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
globenewswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.